



#9  
6-7-01  
P.2

PATENT  
ATTORNEY DOCKET NO. 50069/002002

Certificate of Mailing: Date of Deposit: 5/23/01

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Christine M. Citro

Printed name of person mailing correspondence

*Christine M. Citro*

Signature of person mailing correspondence

TECH CENTER 1600/2900

JUN 01 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Anthony P. Adamis, et al.

Art Unit: 1632

Serial No.: 09/478,099

Examiner: A. Baker

Filed: January 5, 2000

Title: TARGETED TRANSSCLERAL CONTROLLED RELEASE DRUG  
DELIVERY TO THE RETINA AND CHOROID

Assistant Commissioner for Patents  
Washington, D.C. 20231

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement mailed March 28, 2001, applicants elect, without traverse, Group II, claims 1-18, wherein the agent is a nucleic acid.

If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: May 23, 2001

*[Signature]*  
Paul T. Clark

Reg. No. 30,162

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

\\Clark-w2k1\documents\50069\50069.002002 Reply to Restriction Requirement.wpd



21559

PATENT TRADEMARK OFFICE